Similarly, PEG-ADA, an FDA-approved enzyme replacement therapy for children with severe combined immunodeficiency (SCID), has been shown to alleviate adenosine-mediated suppression of CD8+ T cells and enhance responses to anti-PD-1 therapy [252]. The gene discussed is ADA; the disease is severe combined immunodeficiency.